lead-innovation-banner

Lead Innovation

Vaccines have significantly reduced the threat of diseases that were once widespread and oftentimes fatal. Today, more people benefit from safe and efficacious vaccines than ever before — and the list of diseases that vaccines can help prevent continues to grow. Vaccines prevent infections from serious, life-threatening diseases and they can also help reduce health care costs to both patients and the broader health care system by reducing the incidence of vaccine-preventable illness.

Bharat Biotech till date has distributed 2 billion
doses to over 65 countries

The development of vaccines to prevent serious diseases, is an extraordinary story of medical achievement — one in which Bharat Biotech and its ‘legacy’ companies have played a critical role for more than a decade.

Bharat Biotech has pledged to supply its
Rotavirus Vaccine at $1 to global agencies

Today, Bharat is helping to usher in a new era of vaccine innovation both to prevent and treat diseases. Focused around neglected diseases of the developing world, Bharat will continue to push the boundaries of innovation, to pursue the next scientific breakthrough for the prevention of such neglected disease. In addition, Bharat is developing vaccines that target ‘Rotavirus’, the common cause of severe diarrhea among infants, which till date causes more than 600,000 child mortality cases globally each year.

 
Bharat is also working on a vaccine for Staphylococcus aureus — the leading cause of hospital-acquired infections. The company also announced that it is developing a Thrombolytic Agent for the treatment of Myocardial Infarction. With an intent to combat region specific and neglected diseases and not necessarily competition, Bharat Biotech is working on developing vaccines for Chikunguniya, Chandipura, Dengue and Japanese Encephalitis; more as a social commitment and responsibility towards society.

Malaria imposes a great socio-economic burden on humanity, with six other diseases like diarrhea, HIV/AIDS, tuberculosis, measles, hepatitis B and pneumonia which account for 85% of Global infectious disease burden. About 36% of the world population i.e. 2020 million is exposed to the risk of contracting malaria in ~ 90 countries. World Health Organization estimates 300–500 million malaria cases annually.

Bharat in collaboration with Malaria Vaccine Initiative (MVI) of Bill & Melinda Gates Foundation through Program for Appropriate Technologies in Health (PATH) has started working on Malaria Vaccine Development. Similarly, it has produced a cell culture based HINI vaccine for the pandemic disease which spread in Asia.

Patient safety issues have always been a key focus of Bharat, particularly when it comes to pediatric immunization program; more recently the company produced it’s first cesium and mercury free Hepatitis B vaccine and now it is on the anvil of developing the world’s first Typhoid Conjugate Vaccine, for immunizing children below 2 years of age.

Bharat will continue its journey to combat against global mortality and morbidity of the Developing World with special focus on neglected diseases. With lead innovation aimed at bringing equity in global health, Bharat will strive to bridge the gap between the developed and developing world with newer research based products in vaccines and bio-therapeutics at a affordable price for those who need it most.